

GeNeuro publishes the English version of its 2017 Registration Document

Geneva, Switzerland, 26 April 2018 – 7:15 pm CEST GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, including multiple sclerosis and Type 1 diabetes, publishes its 2017 Registration Document, in English, which has been filed on April 26, 2018, with the “Autorité des Marchés Financiers (AMF)”.

This document is available to the public free of charge, as provided for in applicable legislation, and may be viewed and downloaded on the Company’s website www.geneuro.com

The 2017 Registration Document includes the annual financial report, the report of the Chairman of the Board of Directors on the conditions for preparing and organizing the Board’s activities and the internal control procedures, the Management Report, the auditors’ reports and information about fees paid to statutory auditors, as well as the resolutions submitted to the Annual Shareholders’ Meeting of May 24, 2018.

About GeNeuro

GeNeuro’s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis and Type 1 Diabetes, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has 29 employees and rights to 16 patent families protecting its technology. For more information, visit: www.geneuro.com

GeNeuro’s contacts:

GeNeuro	NewCap (France)	Halsin Partners	LifeSci Advisors
Jesús Martin-Garcia Chairman and CEO +41 22 552 4800 investors@geneuro.com	Julien Perez (investors) +33 1 44 71 98 52 Nicolas Merigeau (media) +33 1 44 71 94 98 geneuro@newcap.eu	Mike Sinclair (media) +44 20 7318 2955 msinclair@halsin.com	Chris Maggos (investors) +1 646 597 6970 +41 79 367 6254 chris@lifesciadvisors.com